news search contents meditorial ask the doctor discuss register help home
The Doctor Will See You Now Navigation
Senior LivingWomen's HealthNutritionBioethicsBehaviorSpecialists

IN THIS ARTICLE

Diagnosis

Management

Kegel exercises

 Discussion


The Doctor's Health Tip
Dark patches of skin above the temples may be a sign of Giant Cell Arteritis, a serious, though treatable, condition. more...


OTHER TOPICS

Parkinson's disease
Urinary Incontinence

John E. Morley, M.D.

Incontinence, the inability to restrain the discharge of urine, is an extremely common and highly treatable disorder. There are two types:
  1. acute, which is often related to an associated disease
  2. chronic persistent incontinence.
Acute Incontinence
Acute incontinence appears suddenly and is not rare in older individuals. It is usually associated with an underlying disease. The causes of acute incontinence are best remembered by the mnemonic, DRIP:

Drugs, delirium
Retention of urine, Restricted mobility
Impaction, Infection
Polyuria, Prostatism
The treatment of acute incontinence includes frequent toileting and treatment of the underlying cause. Catheterization should be avoided as it increases the likelihood of hospital-acquired infections.

Chronic Incontinence
The types of chronic incontinence are:
  • Urge incontinence, the most common form of incontinence, is characterized by loss of small or large volumes of urine when the individual has insufficient warning, following the first urge to void, to allow him or her to reach the toilet.
  • Stress incontinence occurs in women who usually have had children and is characterized by loss of small volumes of urine following coughing, sneezing or other maneuvers that increase intra-abdominal pressure. It happens because the internal urethral sphincter, the circular band of muscle that surrounds the bladder opening, has lost muscle tone and pushed outside of the abdominal cavity.
  • Reflex incontinence occurs in persons with spinal cord damage. Their bladders do not receive, via the spinal cord, the message to stop urination.
  • Functional incontinence occurs when either a person's physical or mental state deters the person from urinating in the toilet, i.e., the person lacks the physical ability to reach the toilet or lacks an adequate thought process to go to the toilet when having the urge to urinate. Causes include strokes, dementia and depression.
  • Overflow incontinence is of two types:
    1. Neurogenic - the individual does not receive a message that the bladder is full and a signal to urinate is not transmitted. This occurs in persons with autonomic neuropathy.
    2. Obstructive - prostate enlargement is the usual cause.
Diagnosis
A careful history by the doctor and bedside investigation of urine flow (urodynamics) are necessary:

The patient empties their bladder and then, lying on the examination table with a bedpan underneath them, is asked to cough. Loss of urine indicates stress incontinence. The patient is then catheterized and urine drained. If there is more than 100 cc, the person has overflow incontinence. A 50 cc syringe is then attached to the catheter and the bladder is filled with normal saline. The patient is asked to indicate when the first urge to urinate is felt. If this occurs before 300 cc or if it is accompanied by immediate, vigorous movement of the bubble in the syringe, the diagnosis is urge incontinence. When 400 cc of saline has been instituted into the bladder, the catheter is removed and the person is asked to cough again. Loss of urine = stress incontinence. The patient is then asked to void into a container. If greater than 100 cc, then overflow incontinence is diagnosed.

Management of Incontinence
Table 1 below provides a useful summary of the treatments for various types of incontinence.



Finally, remember that many older persons develop DHIC (detrusor hypercontractibility and impaired contraction), a combination of urge and neurogenic incontinence. Treatment depends on needs of patient, e.g., if being wet during the day is unacceptable, then oxybutynin is given in the morning and bethanechol in the evening.

Conclusion
Urinary incontinence is a straightforward condition, its cause easily identified and treated. Treatment can have a major impact on the older person's quality of life. Proactive preventive Kegel exercises may be helpful.

October 1999 Email this article to a friend

References
1. Jankovic J. The extrapyramidal disorders. In: Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia, Pa: WB Saunders Co; 1996;2040-2046. return

2. Adams RD, Victor M, Ropper AH. Principles of Neurology. 6th ed. New York, NY: McGraw-Hill; 1997:1067-1078. return

3. Calne DB. Initiating treatment for idiopathic Parkinsonism. Neurology. 1994;44(7):S19-S22. return

4. Goetz CG, Jankovic J. Koller WC, Lieberman A, Taylor RB, Waters CH. Nonpharmacological approaches to the management of Parkinson's disease. Continum. 1995;1(4):114-129. return

5. Waters CH. Management of patients with complicated Parkinson's disease. Syllabus, Course 127. American Academy of Neurology Annual Meeting, Seattle, WA 1995:33-42. return

6. Kordower JH, Goetz CG, Freeman TB, Olanow CW. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol. 1997;144:41-46. return

7. Ahlskog JE. Treatment options for mild and moderate Parkinson's disease. Syllabus, Course 236. American Academy of Neurology 48th Annual Meeting: San Francisco, Calif: 1996;25-42. return

8. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(3, suppl 3):S13-S21. return

9. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology, 1997 (suppl 1):S58-S62. return

10. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders: Parkinson's disease. In: Hardman JG, Limbird LE, Molinoff N , Ruddon RW, Gilmon AG, ed. Goodman and Gilman's The Pharmacologica Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:506-513. return

11. Koller WC. Treatment of Parkinson's disease: Mild and moderate treatment options. Syllabus. Course 127. American Academy of Neurology Annual Meeting; 1995; Seattle, Wash. return

12. Stern MB. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease overview. Neurology, 1997;;40 (1 suppl 1):S2-S9.return

13. Koller WC. Neuroprotective therapy for Parkinson's. return

14. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ. 1995;311:1602-1607. return

15. Blanpied TA, Boeckman FA, Aizenman E, Johnson JW. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 1997;77:309-323. return

16. Golbe LI, Sage JI. Medical treatment of Parkinson's disease. In: Kurlan R, ed. Treatment of Movement Disorders. Philadelphia, PA: JB Lippincott Co; 1995:1-56. return

17. Schenkman M, Toni M., et al. Exercise to improve spinal flexibility and function for people with Parkinson's Disease: A randomized, controlled trial. J Am Geriat Soc 46:1207-1216, 1998. return

18. Snyder SH, Sabatini DM, Lai MM, Steiner JP, Hamilton GS, Suzdak PD: Neural actions of immunophilin ligands. Trends in Pharmacol Sci 19(1):21-26, 1998. return

19. Pratt WB. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Bio & Med 217(4):420-434, 1998. return



  

  NEWS   SEARCH   CONTENTS   MEDITORIAL   ASK   DISCUSS   REGISTER   HELP   HOME 

© 2008 interMDnet Corporation. All Rights Reserved.  PRIVACY POLICY